These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16127074)

  • 1. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
    Hammond JL; Parikh UM; Koontz DL; Schlueter-Wirtz S; Chu CK; Bazmi HZ; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3930-2. PubMed ID: 16127074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase.
    Ray AS; Murakami E; Peterson CN; Shi J; Schinazi RF; Anderson KS
    Antiviral Res; 2002 Dec; 56(3):189-205. PubMed ID: 12406504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
    Shi J; McAtee JJ; Schlueter Wirtz S; Tharnish P; Juodawlkis A; Liotta DC; Schinazi RF
    J Med Chem; 1999 Mar; 42(5):859-67. PubMed ID: 10072683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design.
    Kukhanova M; Li X; Chen SH; King I; Doyle T; Prusoff W; Cheng YC
    Mol Pharmacol; 1998 May; 53(5):801-7. PubMed ID: 9584205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.
    Erickson-Viitanen S; Wu JT; Shi G; Unger S; King RW; Fish B; Klabe R; Geleziunas R; Gallagher K; Otto MJ; Schinazi RF
    Antivir Chem Chemother; 2003 Jan; 14(1):39-47. PubMed ID: 12790515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
    Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
    J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP.
    Murakami E; Ray AS; Schinazi RF; Anderson KS
    Antiviral Res; 2004 Apr; 62(1):57-64. PubMed ID: 15026203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
    Andreatta KN; Goodman DD; Miller MD; White KL
    Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
    Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
    Anderson KS
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.
    Shi J; Mathew JS; Tharnish PM; Rachakonda S; Pai SB; Adams M; Grier JP; Gallagher K; Zhang H; Wu JT; Shi G; Geleziunas R; Erickson-Viitanen S; Stuyver L; Otto MJ; Watanabe KA; Schinazi RF
    Antivir Chem Chemother; 2003 Mar; 14(2):81-90. PubMed ID: 12856919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.